

Vincent Lo Re

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1415620/publications.pdf>

Version: 2024-02-01

159
papers

4,810
citations

117453

34
h-index

118652

62
g-index

162
all docs

162
docs citations

162
times ranked

7352
citing authors

#	ARTICLE	IF	CITATIONS
1	The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e101554.	1.1	362
2	Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLoS Medicine, 2020, 17, e1003379.	3.9	271
3	Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus-Monoinfected Patients. Annals of Internal Medicine, 2014, 160, 369-379.	2.0	214
4	A Simple, Dynamic Measure of Antiretroviral Therapy Adherence Predicts Failure to Maintain HIV-1 Suppression. Journal of Infectious Diseases, 2006, 194, 1108-1114.	1.9	175
5	Eosinophilic meningitis. American Journal of Medicine, 2003, 114, 217-223.	0.6	161
6	HCV epidemiology in high-risk groups and the risk of reinfection. Journal of Hepatology, 2016, 65, S33-S45.	1.8	146
7	The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology, 2018, 67, 2244-2253.	3.6	137
8	Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiology and Drug Safety, 2011, 20, 689-699.	0.9	123
9	Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiology and Drug Safety, 2012, 21, 765-769.	0.9	121
10	Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance. Clinical Gastroenterology and Hepatology, 2016, 14, 1035-1043.	2.4	111
11	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV, 2019, 6, e93-e104.	2.1	94
12	Population-Representative Incidence of Drug-Induced Acute Liver Failure Based on an Analysis of an Integrated Health Care System. Gastroenterology, 2015, 148, 1353-1361.e3.	0.6	90
13	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. Journal of the American Academy of Dermatology, 2021, 84, 1254-1268.	0.6	88
14	Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus-Infected, and Uninfected Patients. Clinical Infectious Diseases, 2014, 58, 1449-1458.	2.9	77
15	The Yale cTAKES extensions for document classification: architecture and application. Journal of the American Medical Informatics Association: JAMIA, 2011, 18, 614-620.	2.2	75
16	Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. Aids, 2018, 32, 739-749.	1.0	72
17	Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion. JAMA Internal Medicine, 2015, 175, 178.	2.6	71
18	Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. Open Forum Infectious Diseases, 2018, 5, ofy076.	0.4	69

#	ARTICLE	IF	CITATIONS
19	Risk of hip fracture associated with hepatitis c virus infection and hepatitis C/human immunodeficiency virus coinfection. <i>Hepatology</i> , 2012, 56, 1688-1698.	3.6	68
20	Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes. <i>Clinical Infectious Diseases</i> , 2009, 48, 186-193.	2.9	67
21	Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. <i>American Journal of Medicine</i> , 2016, 129, 283-291.e5.	0.6	65
22	Prevalence, Risk Factors, and Outcomes for Occult Hepatitis B Virus Infection Among HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 315-320.	0.9	64
23	Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 807-814.	0.9	60
24	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw531.	2.9	60
25	Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hyatt's Law and a New Prognostic Model. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2360-2368.	2.4	57
26	Relationship Between Adherence to Hepatitis C Virus Therapy and Virologic Outcomes. <i>Annals of Internal Medicine</i> , 2011, 155, 353.	2.0	53
27	Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 103-107.	0.9	50
28	Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus-Coinfected Veterans. <i>Clinical Infectious Diseases</i> , 2014, 58, 719-727.	2.9	50
29	Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 861-872.	0.9	46
30	Bilirubin Is Inversely Associated With Cardiovascular Disease Among HIV-Positive and HIV-Negative Individuals in VACS (Veterans Aging Cohort Study). <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	43
31	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	0.6	43
32	Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES. <i>Digestive Diseases and Sciences</i> , 2016, 61, 930-936.	1.1	39
33	FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2512-2517.	1.1	37
34	Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1266-1274.	0.3	36
35	Incidence, determinants and outcomes of pregnancy-associated hepatitis B flares: A regional hospital-based cohort study. <i>Liver International</i> , 2018, 38, 813-820.	1.9	34
36	Real-world data: Assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 717-720.	0.9	34

#	ARTICLE	IF	CITATIONS
37	Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. <i>Aids</i> , 2009, 23, 2191-2198.	1.0	33
38	Eosinophilic Meningitis Due to <i>Angiostrongylus cantonensis</i> in a Returned Traveler: Case Report and Review of the Literature. <i>Clinical Infectious Diseases</i> , 2001, 33, e112-e115.	2.9	31
39	Management Complexities of HIV/Hepatitis C Virus Coinfection in the Twenty-First Century. <i>Clinics in Liver Disease</i> , 2008, 12, 587-609.	1.0	31
40	Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. <i>Aids</i> , 2006, 20, 1333-1336.	1.0	29
41	Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. <i>Journal of Hepatology</i> , 2020, 73, 277-284.	1.8	29
42	Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. <i>Clinical Infectious Diseases</i> , 2017, 65, 64-72.	2.9	28
43	Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2019, 73, 815-826.	2.1	27
44	Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 962-968.	0.6	26
45	FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. <i>Hepatology</i> , 2017, 66, 1286-1295.	3.6	26
46	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021, 4, e2037512.	2.8	26
47	A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 827-837.	0.9	26
48	Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. <i>Hepatology</i> , 2021, 74, 1190-1202.	3.6	26
49	The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. <i>Antiviral Therapy</i> , 2010, 15, 91-99.	0.6	25
50	Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2014, 61, 210-218.	1.8	25
51	FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 184-191.	1.6	25
52	Bayesian Nonparametric Generative Models for Causal Inference with Missing at Random Covariates. <i>Biometrics</i> , 2018, 74, 1193-1202.	0.8	23
53	Infected Branchial Cleft Cyst Due to <i>Bordetella bronchiseptica</i> in an Immunocompetent Patient. <i>Journal of Clinical Microbiology</i> , 2001, 39, 4210-4212.	1.8	22
54	Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection. <i>Current HIV/AIDS Reports</i> , 2020, 17, 405-414.	1.1	22

#	ARTICLE	IF	CITATIONS
55	Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women. <i>Journal of Infectious Diseases</i> , 2015, 212, 924-933.	1.9	21
56	HIV, Aging, and Viral Coinfections: Taking the Long View. <i>Current HIV/AIDS Reports</i> , 2016, 13, 269-278.	1.1	21
57	Fever in the returned traveler. <i>American Family Physician</i> , 2003, 68, 1343-50.	0.1	21
58	Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1202-1215.	0.9	20
59	Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-coinfected patients initiating tenofovir-based therapy. <i>Journal of Viral Hepatitis</i> , 2014, 21, 288-296.	1.0	20
60	Severe Weight Gain, Lipodystrophy, Dyslipidemia, and Obstructive Sleep Apnea in a Human Immunodeficiency Virus-infected Patient Following Highly Active Antiretroviral Therapy. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 111-114.	1.7	19
61	Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 999-1003.	0.9	19
62	Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 285-293.	1.5	19
63	Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020, 35, 2025-2034.	1.3	19
64	Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e639-e650.	2.0	18
65	Colorectal cancer incidence and screening in US Medicaid patients with and without HIV infection. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 716-722.	0.6	17
66	Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 676-683.	0.9	17
67	Global covid-19 vaccine rollout and safety surveillance—how to keep pace. <i>BMJ, The</i> , 2021, 373, n1416.	3.0	17
68	Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. <i>International Journal of Infectious Diseases</i> , 2009, 13, 449-455.	1.5	16
69	Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000–2007. <i>Annals of Epidemiology</i> , 2014, 24, 418-423.	0.9	16
70	Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000400.	1.2	16
71	Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. <i>PLoS ONE</i> , 2020, 15, e0228471.	1.1	16
72	Eosinophilic Meningitis due to <i>Gnathostoma spinigerum</i> . <i>Journal of Infection</i> , 2002, 45, 117-120.	1.7	15

#	ARTICLE	IF	CITATIONS
73	Incidence and Risk Factors for Weight Loss During Dual HIV/Hepatitis C Virus Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 44, 344-350.	0.9	15
74	Increased risk of hip fracture associated with dually treated <scp>HIV</scp>/hepatitis <scp>B</scp> virus coinfection. <i>Journal of Viral Hepatitis</i> , 2015, 22, 936-947.	1.0	15
75	HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. <i>Journal of the National Cancer Institute</i> , 2020, 112, 747-755.	3.0	15
76	HIV Infection, Antiretroviral Therapy Initiation and Longitudinal Changes in Biomarkers of Organ Function. <i>Current HIV Research</i> , 2014, 12, 50-59.	0.2	14
77	Trends in Treatment Uptake and Provider Specialty for Hepatitis C Virus (HCV) Infection in the Veterans Affairs Healthcare System: Results From the Electronically Retrieved Cohort of HCV-Infected Veterans (ERCHIVES). <i>Clinical Infectious Diseases</i> , 2019, 68, 857-859.	2.9	14
78	Determinants of Liver Complications Among HIV/Hepatitis B Virusâ€œCoinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 71-80.	0.9	14
79	Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers. <i>HIV Clinical Trials</i> , 2009, 10, 25-32.	2.0	14
80	Acetaminophen receipt among HIVâ€œinfected patients with advanced hepatic fibrosis. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1352-1356.	0.9	13
81	Development and Usability of a Smartphone Application for Tracking Antiretroviral Medication Refill Data for Human Immunodeficiency Virus. <i>Methods of Information in Medicine</i> , 2017, 56, 351-359.	0.7	13
82	Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. <i>Arthritis and Rheumatology</i> , 2020, 72, 1067-1071.	2.9	13
83	Hepatic Decompensation in Patients With HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) Triple Infection Versus HIV/HCV Coinfection and the Effect of Anti-HBV Nucleos(t)ide Therapy. <i>Clinical Infectious Diseases</i> , 2014, 59, 1027-1031.	2.9	12
84	Ascertainment and Verification of End-Stage Renal Disease and End-Stage Liver Disease in the North American AIDS Cohort Collaboration on Research and Design. <i>AIDS Research and Treatment</i> , 2015, 2015, 1-11.	0.3	12
85	Prevalence and risk factors for patient-reported joint pain among patients with HIV/Hepatitis C coinfection, Hepatitis C monoinfection, and HIV monoinfection. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 93.	0.8	12
86	Determinants of stigma among patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1179-1189.	1.0	12
87	Impact of hepatitis C virus treatment on the risk of nonâ€œhepatic cancers among hepatitis C virusâ€œinfected patients in the US. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1592-1602.	1.9	12
88	Hypereosinophilia associated with cardiac rhabdomyosarcoma. <i>American Journal of Hematology</i> , 2003, 74, 64-67.	2.0	11
89	Strategies for the Elimination of Hepatitis C Virus Infection as a Public Health Threat in the United States. <i>Current Hepatology Reports</i> , 2018, 17, 111-120.	0.4	11
90	Validity of <scp>ICDâ€œ10â€œCM</scp> diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 899-909.	0.9	11

#	ARTICLE	IF	CITATIONS
91	A semiparametric modeling approach using Bayesian Additive Regression Trees with an application to evaluate heterogeneous treatment effects. <i>Annals of Applied Statistics</i> , 2019, 13, 1989-2010.	0.5	11
92	Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv109.	0.4	10
93	Incidence of transaminitis among HIV-infected patients with occult hepatitis B. <i>Journal of Clinical Virology</i> , 2008, 43, 32-36.	1.6	9
94	The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders. <i>Hepatology</i> , 2021, 74, 566-581.	3.6	9
95	Self-reported hepatitis B and C virus infections had low sensitivity among HIV-infected patients. <i>Journal of Clinical Epidemiology</i> , 2007, 60, 294-299.	2.4	8
96	The role of academia and the research community in assisting the food and drug administration to ensure U.S. drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 818-825.	0.9	8
97	Validity of Primary Immunodeficiency Disease Diagnoses in United States Medicaid Data. <i>Journal of Clinical Immunology</i> , 2015, 35, 566-572.	2.0	8
98	Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status. <i>Clinical Infectious Diseases</i> , 2017, 65, 1542-1550.	2.9	8
99	Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people. <i>BMC Gastroenterology</i> , 2019, 19, 52.	0.8	8
100	Natural History of Patients with Low-Level HIV Viremia on Antiretroviral Therapy. <i>AIDS Patient Care and STDs</i> , 2004, 18, 436-442.	1.1	7
101	Epidemiologic research using probabilistic outcome definitions. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 19-26.	0.9	7
102	Evaluating Hepatitis B Virus Reactivation During Solid Tumor Chemotherapy: Evidence to Guide Pretreatment Hepatitis B Screening and Prophylaxis. <i>Annals of Internal Medicine</i> , 2016, 164, 64.	2.0	7
103	Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1172-1181.	0.9	7
104	Prediction of post-vaccination Guillain-Barré syndrome using data from a passive surveillance system. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 602-609.	0.9	7
105	Identifying the vector of Lyme disease. <i>American Family Physician</i> , 2004, 69, 1935-7.	0.1	7
106	Adherence to Hepatitis C Virus Therapy in HIV/Hepatitis C-Coinfected Patients. <i>AIDS and Behavior</i> , 2013, 17, 94-103.	1.4	6
107	Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 8.	1.0	6
108	Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx012.	0.4	6

#	ARTICLE	IF	CITATIONS
109	Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1147-1150.	0.9	6
110	Association between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e417-e425.	2.0	6
111	Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. <i>Journal of Hepatology</i> , 2021, 75, 1312-1322.	1.8	6
112	Travel immunizations. <i>American Family Physician</i> , 2004, 70, 89-99.	0.1	6
113	Economic Analysis of Hepatitis B Screening and Treatment. <i>Clinical Infectious Diseases</i> , 2011, 52, 1307-1309.	2.9	5
114	Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 115-123.	0.8	5
115	Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1328-1335.	0.9	5
116	Prevention of malaria in travelers. <i>American Family Physician</i> , 2003, 68, 509-14.	0.1	5
117	Predictors of Severe Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2004, 38, 1789-1790.	2.9	4
118	Type III hyperlipoproteinemia unmasked by HIV anti-retroviral therapy. <i>American Journal of Medicine</i> , 2005, 118, 691-692.	0.6	4
119	Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection. <i>Annals of Epidemiology</i> , 2018, 28, 808-811.	0.9	4
120	Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 71-78.	1.1	4
121	Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1353-1360.	2.3	4
122	Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar. <i>BMJ Global Health</i> , 2021, 6, e004181.	2.0	4
123	The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 873-881.	0.5	4
124	Obesity Is Not Associated with Impaired Immune Response to Influenza Vaccination in HIV-Infected Persons. <i>AIDS Research and Treatment</i> , 2015, 2015, 1-7.	0.3	3
125	Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3159-3174.	1.1	3
126	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 338-346.	0.3	3

#	ARTICLE	IF	CITATIONS
127	The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection. PLoS ONE, 2021, 16, e0258143.	1.1	3
128	Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. Pharmacoepidemiology and Drug Safety, 2022, 31, 214-224.	0.9	3
129	Anemia during treatment of hepatitis C in HIV-infected patients. Aids Reader, 2004, 14, 555-7, 562, 565-71.	0.3	3
130	Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal of Substance Abuse Treatment, 2016, 68, 62-67.	1.5	2
131	Is Moderate Alcohol Consumption Safe for Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women?. Clinical Infectious Diseases, 2017, 65, 2057-2059.	2.9	2
132	HIV- and HCV-specific markers and echocardiographic pulmonary artery systolic pressure among United States veterans. Scientific Reports, 2020, 10, 18729.	1.6	2
133	Development and validation of case-finding algorithms to identify prosthetic joint infections after total knee arthroplasty in Veterans Health Administration data. Pharmacoepidemiology and Drug Safety, 2021, 30, 1184-1191.	0.9	2
134	Willingness to Undergo a Repeat Liver Biopsy Among HIV/Hepatitis C Virus-coinfected and Hepatitis C Virus-monoinfected Patients. Journal of Clinical Gastroenterology, 2013, 47, 457-460.	1.1	1
135	Should everyone ageing with HIV take a statin?. Lancet HIV, the, 2015, 2, e36-e37.	2.1	1
136	Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment. Clinical Infectious Diseases, 2016, 64, ciw814.	2.9	1
137	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 918-919.	2.4	1
138	The Incidence of Hepatocellular Carcinoma Is not Increased in Individuals with Chronic Hepatitis C After Treatment with Interferon-free Regimens: an ERCHIVES Study. Open Forum Infectious Diseases, 2017, 4, S41-S41.	0.4	1
139	Validation of health outcomes of interest in healthcare databases. , 2021, , 207-218.		1
140	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. Drugs and Therapy Perspectives, 2021, 37, 338-346.	0.3	1
141	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 396-404.	0.9	1
142	Profiling real-world data sources for pharmacoepidemiologic research: A call for papers. Pharmacoepidemiology and Drug Safety, 2022, 31, 929-931.	0.9	1
143	William Pepper Jr, MD (1843-1898): portrait of a nineteenth-century medical educator. Journal of Medical Biography, 2006, 14, 169-177.	0.1	0
144	1603Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection. Open Forum Infectious Diseases, 2014, 1, S427-S427.	0.4	0

#	ARTICLE	IF	CITATIONS
145	645 Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women. Open Forum Infectious Diseases, 2014, 1, S33-S33.	0.4	0
146	Reply to Marcellin et al. Clinical Infectious Diseases, 2014, 59, 1192-1193.	2.9	0
147	Risk of Acute Liver Injury With Modern Antiretroviral Therapy. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
148	The Risk of Acute Liver Injury With Statin Use in Chronic Hepatitis C Virus Infection. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
149	The Reply. American Journal of Medicine, 2017, 130, e369.	0.6	0
150	2224. Receipt and Virologic Outcomes of HCV Direct-Acting Antivirals by Alcohol Use and HIV Status. Open Forum Infectious Diseases, 2018, 5, S657-S658.	0.4	0
151	2219. Treatment Uptake for Hepatitis C Virus Infection in the Veterans Affairs Healthcare System in the Era of Directly Acting Antiviral Agents: An ERCHIVES Study. Open Forum Infectious Diseases, 2018, 5, S655-S656.	0.4	0
152	Mortality and Kidney Transplantation Outcomes among Chronic Dialysis Patients who are Seropositive for Hepatitis C Virus. Transplantation, 2018, 102, S154.	0.5	0
153	2896. Reduction in Liver-related Mortality Among HCV Infected Persons Is Driven by Attainment of SVR Independent of the Regimen Used: Results from the ERCHIVES Cohort. Open Forum Infectious Diseases, 2019, 6, S82-S82.	0.4	0
154	Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 530-534.	0.9	0
155	Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?" Journal of Hepatology, 2022, , .	1.8	0
156	Title is missing!. , 2020, 17, e1003379.		0
157	Title is missing!. , 2020, 17, e1003379.		0
158	Title is missing!. , 2020, 17, e1003379.		0
159	Title is missing!. , 2020, 17, e1003379.		0